Request for information

FTC, HHS Extend Public Comment Period on Generic Drug Shortages and Competition Request for Information

Retrieved on: 
Tuesday, April 2, 2024
System, Request for information, Social media, RFI, Comment, HHS, Policy, Blog, News, Federal Trade Commission, FTC

The Federal Trade Commission and the U.S. Department of Health and Human Services (HHS) are extending the deadline for the public to comment on a joint Request for Information (RFI) that seeks to understand how the practices of group purchasing organizations (GPOs) and drug wholesalers may be contributing to generic drug shortages.

Key Points: 
  • The Federal Trade Commission and the U.S. Department of Health and Human Services (HHS) are extending the deadline for the public to comment on a joint Request for Information (RFI) that seeks to understand how the practices of group purchasing organizations (GPOs) and drug wholesalers may be contributing to generic drug shortages.
  • In the RFI, the FTC and HHS are seeking public comment regarding market concentration among large health care GPOs and drug wholesalers, as well as information detailing their contracting practices.
  • The comment period was originally set to end on April 15, 2024.
  • The Federal Trade Commission develops policy initiatives on issues that affect competition, consumers, and the U.S. economy.

FTC Issues Infant Formula Supply Disruptions Report

Retrieved on: 
Tuesday, April 2, 2024
Commission, Information, Request for information, Social media, Policy, Blog, News, Infant, Federal Trade Commission, FTC

Today, the Federal Trade Commission issued a report on market factors relevant to infant formula supply disruptions, which details aspects of the U.S. infant formula market that rendered it vulnerable to supply disruptions in 2022.

Key Points: 
  • Today, the Federal Trade Commission issued a report on market factors relevant to infant formula supply disruptions, which details aspects of the U.S. infant formula market that rendered it vulnerable to supply disruptions in 2022.
  • The report also outlines considerations for policymakers to help create a more resilient infant formula supply going forward.
  • The Commission’s report follows a Request for Information launched in 2022 which solicited comments from members of the public, industry, trade groups, and academics on a variety of issues related to the disruptions and the infant formula market more broadly.
  • These comments informed the FTC’s analysis as the Commission considered whether certain features of the infant formula market contributed to the industry-wide disruptions in 2022, and how competition-based reforms may promote greater resiliency.

FTC, HHS Extend Public Comment Period on Generic Drug Shortages and Competition Request for Information

Retrieved on: 
Tuesday, April 2, 2024
System, Request for information, Social media, RFI, Comment, HHS, Policy, Blog, News, Federal Trade Commission, FTC

The Federal Trade Commission and the U.S. Department of Health and Human Services (HHS) are extending the deadline for the public to comment on a joint Request for Information (RFI) that seeks to understand how the practices of group purchasing organizations (GPOs) and drug wholesalers may be contributing to generic drug shortages.

Key Points: 
  • The Federal Trade Commission and the U.S. Department of Health and Human Services (HHS) are extending the deadline for the public to comment on a joint Request for Information (RFI) that seeks to understand how the practices of group purchasing organizations (GPOs) and drug wholesalers may be contributing to generic drug shortages.
  • In the RFI, the FTC and HHS are seeking public comment regarding market concentration among large health care GPOs and drug wholesalers, as well as information detailing their contracting practices.
  • The comment period was originally set to end on April 15, 2024.
  • The Federal Trade Commission develops policy initiatives on issues that affect competition, consumers, and the U.S. economy.

Aeros Launches Site Selection For Airship Assembly Facility

Retrieved on: 
Saturday, March 9, 2024
Carbon, Public expenditure, Transport, LOS, Request for information, Aviation, Airline

LOS ANGELES, March 9, 2024 /PRNewswire-PRWeb/ -- Aeros, a leading innovator in the airship manufacturing industry, is officially initiating the site selection process for its new state-of-the-art airship manufacturing and assembly facility. The company is issuing a Request for Information to identify potential locations capable of supporting the advanced infrastructure required for the production of its zero-emission electric variable buoyancy cargo airships (eVBA).

Key Points: 
  • Aeros, a leading innovator in the airship manufacturing industry, is officially initiating the site selection process for its new zero-emission cargo airship manufacturing and assembly facility.
  • LOS ANGELES, March 9, 2024 /PRNewswire-PRWeb/ -- Aeros, a leading innovator in the airship manufacturing industry, is officially initiating the site selection process for its new state-of-the-art airship manufacturing and assembly facility.
  • Strategic Site Selection: Aeros is seeking partnerships with states and communities capable of hosting the facility, with the potential for expansion up to 200 acres.
  • Job Creation and Economic Impact: The establishment of the facility is expected to generate thousands of high-paying jobs in the cleantech aviation and aerospace manufacturing sector.

Nous Infosystems Recognized as a Major Contender in Everest Group Application Transformation Services PEAK Matrix® Assessment 2024 - North America

Retrieved on: 
Tuesday, February 20, 2024
Request for information, EVP, RFI, Nous, Microsoft, Development, Management

EDISON, N.J., Feb. 20, 2024 /PRNewswire/ -- Nous Infosystems , a leading global IT solutions provider delivering innovative technology services and solutions, announced its recognition as a Major Contender in Application Transformation Services PEAK Matrix® Assessment 2024 - North America by Everest Group.

Key Points: 
  • EDISON, N.J., Feb. 20, 2024 /PRNewswire/ -- Nous Infosystems , a leading global IT solutions provider delivering innovative technology services and solutions, announced its recognition as a Major Contender in Application Transformation Services PEAK Matrix® Assessment 2024 - North America by Everest Group.
  • The Everest Application Transformation Services Peak Matrix Assessment, a thorough analysis assessing 28 application transformation service providers, provides valuable insights into the dynamics of the North American landscape.
  • Anurag Chauhan, CEO, Nous Infosystems, expresses, "Being recognized as a Major Contender in Application Transformation Services solidifies our dedication to delivering business-centric solutions.
  • Sreenivasan Narayanan, EVP - Microsoft Global Alliances at Nous Infosystems, adds, "Attaining Major Contender status in Application Transformation Services highlights our operational and technical expertise.

Nous Infosystems Recognized as a Major Contender in Everest Group Application Transformation Services PEAK Matrix® Assessment 2024 - North America

Retrieved on: 
Tuesday, February 20, 2024
Request for information, EVP, RFI, Nous, Microsoft, Development, Management

EDISON, N.J., Feb. 20, 2024 /PRNewswire/ -- Nous Infosystems , a leading global IT solutions provider delivering innovative technology services and solutions, announced its recognition as a Major Contender in Application Transformation Services PEAK Matrix® Assessment 2024 - North America by Everest Group.

Key Points: 
  • EDISON, N.J., Feb. 20, 2024 /PRNewswire/ -- Nous Infosystems , a leading global IT solutions provider delivering innovative technology services and solutions, announced its recognition as a Major Contender in Application Transformation Services PEAK Matrix® Assessment 2024 - North America by Everest Group.
  • The Everest Application Transformation Services Peak Matrix Assessment, a thorough analysis assessing 28 application transformation service providers, provides valuable insights into the dynamics of the North American landscape.
  • Anurag Chauhan, CEO, Nous Infosystems, expresses, "Being recognized as a Major Contender in Application Transformation Services solidifies our dedication to delivering business-centric solutions.
  • Sreenivasan Narayanan, EVP - Microsoft Global Alliances at Nous Infosystems, adds, "Attaining Major Contender status in Application Transformation Services highlights our operational and technical expertise.

FTC, HHS Seek Public Comment on Generic Drug Shortages and Competition Amongst Powerful Middlemen

Retrieved on: 
Wednesday, February 14, 2024
Social media, Hospital, FTC, Physician, Nursing, News, System, Request for information, HHS, Blog, RFI, Federal, Patient, Policy, Federal Trade Commission, ADHD, Regulations.gov, GPO, Cancer, Dietary supplement

In the Request for Information (RFI), the FTC and HHS are seeking public comment regarding market concentration among large health care GPOs and drug wholesalers, as well as information detailing their contracting practices.

Key Points: 
  • In the Request for Information (RFI), the FTC and HHS are seeking public comment regarding market concentration among large health care GPOs and drug wholesalers, as well as information detailing their contracting practices.
  • The joint RFI is asking these questions to help uncover the root causes and potential solutions to drug shortages.
  • “Our inquiry requests information on the factors driving these shortages and scrutinizes the practices of opaque drug middlemen.
  • - Whether and to what extent concentration among GPOs and drug wholesalers has disincentivized suppliers from competing in generic drug markets.

FTC, HHS Seek Public Comment on Generic Drug Shortages and Competition Amongst Powerful Middlemen

Retrieved on: 
Wednesday, February 14, 2024
Social media, Hospital, FTC, Physician, Nursing, News, System, Request for information, HHS, Blog, RFI, Federal, Patient, Policy, Federal Trade Commission, ADHD, Regulations.gov, GPO, Cancer, Dietary supplement

In the Request for Information (RFI), the FTC and HHS are seeking public comment regarding market concentration among large health care GPOs and drug wholesalers, as well as information detailing their contracting practices.

Key Points: 
  • In the Request for Information (RFI), the FTC and HHS are seeking public comment regarding market concentration among large health care GPOs and drug wholesalers, as well as information detailing their contracting practices.
  • The joint RFI is asking these questions to help uncover the root causes and potential solutions to drug shortages.
  • “Our inquiry requests information on the factors driving these shortages and scrutinizes the practices of opaque drug middlemen.
  • - Whether and to what extent concentration among GPOs and drug wholesalers has disincentivized suppliers from competing in generic drug markets.

Employee Fiduciary Launches a Future Value of 401(k) Fees Calculator to Emphasize the Impact of High 401(k) Fees on Retirement Savers' Balances

Retrieved on: 
Tuesday, November 14, 2023
Disclosure, Third-party administrator, TPA, CPC, Comment, QPA, Request, Retirement, Personal fiduciary services, Request for information, Administration, Letter, Financial adviser, Credit

This tool is designed to show retirement savers how much they can increase their savings in retirement by lowering their 401(k) fees today.

Key Points: 
  • This tool is designed to show retirement savers how much they can increase their savings in retirement by lowering their 401(k) fees today.
  • When a 401(k) account pays fees, the saver won't just miss their principal in retirement.
  • The calculator, available now at www.employeefiduciary.com/401k-fee-future-value-calculator , offers users a view of how fees can impact their retirement.
  • This new calculator fits directly into Employee Fiduciary's goal of empowering 401(k) participants to understand the cumulative effect of fees and to advocate for lower fees.

FDA Launches Pilot Program to Help Further Accelerate Development of Rare Disease Therapies

Retrieved on: 
Friday, September 29, 2023
Well, China Biologic Products, CDER, Communication, Drug development, START, Life, Register, CBER, Marketing, Center for Drug Evaluation and Research, New Drug Application, Disability, Center for Biologics Evaluation and Research, ARC, Rare, Adequate Yearly Progress, Federal, Biologics license application, Request for information, Investigational New Drug, Federal Register, Patient, Learning, Effectiveness, FDA, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Support, Education, Food, Safety, Disease, Pharmaceutical industry, Medical device, Research

"These are complex products and we recognize the importance of sponsor communication with the FDA to facilitate development of products for patients with unmet medical needs."

Key Points: 
  • "These are complex products and we recognize the importance of sponsor communication with the FDA to facilitate development of products for patients with unmet medical needs."
  • The FDA has undertaken additional efforts to further enhance and expedite the availability of therapies intended to treat rare diseases.
  • The agency additionally published a docket for stakeholder feedback as part of the Learning and Education to Advance and Empower Rare Disease Drug Developers (LEADER 3D) program under the CDER Accelerating Rare disease Cures (ARC) program .
  • Feedback will be used for the identification of knowledge gaps in rare disease drug development and the development of publicly available resources to inform stakeholders who design and conduct rare disease drug development programs on regulatory considerations surrounding clinical trial design.